CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
ZetaMet™ (ZetaFuse™ Bone Graft)combination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05280067
NCT05280067Phase 2Completed
CompareCT.gov

FEASIBILITY STUDY OF ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN THE SPINAL VERTEBRAL BODY: A PHASE 2A, MULTICENTER, OPEN-LABELED, SINGLE-ARM STUDY

Zetagen Therapeutics, Inc·interventional·Posted Mar 15, 2022·Updated Jan 16, 2026

In Brief

A Phase 2 clinical trial evaluating ZetaMet™ (ZetaFuse™ Bone Graft) for Metastatic Breast Cancer in the Spine. Completed, enrolled 10 participants across 2 sites.

Detailed Summary

ZetaMet™ is indicated for patients with destructive, lytic lesions due to metastatic breast cancer to bone, with or without involvement of other sites, with at least one metastatic lesion located in a vertebral body of the spine, and a Spinal Instability Neoplastic Score (SINS) ≥3 and ≤9. ZetaMet™ is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. ZetaMet™ is only for implantation into the vertebral body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer in the Spine
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMar 15, 2022
Enrollment StartSep 1, 2022
Primary CompletionOct 10, 2025
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 4.3 years ago

Interventions

ZetaMet™ (ZetaFuse™ Bone Graft)combination

ZetaMet™ (ZetaFuse™ Bone Graft) will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.